Immutep receives A$2.5M R&D French Tax Incentive
Filed with ASX · · 2 pages · English
SYDNEY, AUSTRALIA – October 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €1,568,399 (~ A$2,546,929) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Re
Earlier from Immutep
- Immutep expands Part A of TACTI-002 due to positive data
- Immutep to receive GBP4M Milestone Payment from GSK
- Japanese patent granted for LAG525 antibody
- Immutep granted European patent for IMP321 in cancer
- Appendix 4E & 2019 Full Year Statutory Accounts
Later from Immutep
- Immutep presents positive TACTI-mel melanoma trial data
- Appendix 4C - quarterly
- Immutep announces European patent grant for LAG525 antibody
- INSIGHT-004 clinical trial update
- Immutep expands Part C of TACTI-002 due to positive data
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep